192 related articles for article (PubMed ID: 11244326)
41. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
42. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
43. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
[TBL] [Abstract][Full Text] [Related]
44. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
[No Abstract] [Full Text] [Related]
45. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
46. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
47. Utility of bisphosphonates in treating bone metastases.
Merlini G; Turesson I
Med Oncol; 1996 Dec; 13(4):215-21. PubMed ID: 9152972
[TBL] [Abstract][Full Text] [Related]
48. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Thürlimann B
Ann Oncol; 1994; 5 Suppl 7():S45-7. PubMed ID: 7532993
[TBL] [Abstract][Full Text] [Related]
49. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
50. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
51. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
52. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
[TBL] [Abstract][Full Text] [Related]
53. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
54. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
55. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
56. Bisphosphonates: biological response modifiers in breast cancer.
Paterson AH
Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
[TBL] [Abstract][Full Text] [Related]
57. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
58. [The Oxford meta-analysis of 2000: reflections and comments].
Mustacchi G
Tumori; 2005; 91(5):1-9. PubMed ID: 16459647
[No Abstract] [Full Text] [Related]
59. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
[TBL] [Abstract][Full Text] [Related]
60. Bisphosphonates for metastatic bone pain.
Body JJ
Support Care Cancer; 1999 Jan; 7(1):1-3. PubMed ID: 9926966
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
